Bio-Path BPTH Stock
Bio-Path Price Chart
Bio-Path BPTH Financial and Trading Overview
| Bio-Path stock price | 0.04 USD |
| Previous Close | 0.03 USD |
| Open | 0.03 USD |
| Bid | 0.03 USD x 1000000 |
| Ask | 0.04 USD x 1888900 |
| Day's Range | 0.02 - 0.04 USD |
| 52 Week Range | 0.01 - 0.23 USD |
| Volume | 9.14K USD |
| Avg. Volume | 27.39K USD |
| Market Cap | 2.01M USD |
| Beta (5Y Monthly) | -0.28 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.14 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
BPTH Valuation Measures
| Enterprise Value | 2.59M USD |
| Trailing P/E | N/A |
| Forward P/E | -0.00990099 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | N/A |
| Price/Book (mrq) | N/A |
| Enterprise Value/Revenue | N/A |
| Enterprise Value/EBITDA | -0.483 |
Trading Information
Bio-Path Stock Price History
| Beta (5Y Monthly) | -0.28 |
| 52-Week Change | -75.00000000000000000000000000000000% |
| S&P500 52-Week Change | 27.29% |
| 52 Week High | 0.23 USD |
| 52 Week Low | 0.01 USD |
| 50-Day Moving Average | 0.05 USD |
| 200-Day Moving Average | 0.07 USD |
BPTH Share Statistics
| Avg. Volume (3 month) | 27.39K USD |
| Avg. Daily Volume (10-Days) | 50.33K USD |
| Shares Outstanding | 50.3M |
| Float | 49.91M |
| Short Ratio | 0.43 |
| % Held by Insiders | 0.0030% |
| % Held by Institutions | 0.86% |
| Shares Short | 79.35K |
| Short % of Float | 1.37% |
| Short % of Shares Outstanding | 1.37% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor | 1:20 |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2025 |
| Most Recent Quarter (mrq) | March 31, 2026 |
| Next Fiscal Year End | December 31, 2026 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | 0% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -234.50% |
| Return on Equity (ttm) | N/A |
Income Statement
| Revenue (ttm) | N/A |
| Revenue Per Share (ttm) | N/A |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | N/A |
| EBITDA | -5361250 USD |
| Net Income Avi to Common (ttm) | -6092000 USD |
| Diluted EPS (ttm) | -1.14 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 12K USD |
| Total Cash Per Share (mrq) | 0 USD |
| Total Debt (mrq) | 511K USD |
| Total Debt/Equity (mrq) | N/A |
| Current Ratio (mrq) | 0.074 |
| Book Value Per Share (mrq) | -0.908 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -321000 USD |
| Levered Free Cash Flow (ttm) | 2.29M USD |
Profile of Bio-Path
| Country | United States |
| State | TX |
| City | Bellaire |
| Address | 4710 Bellaire Boulevard |
| ZIP | 77401 |
| Phone | 832 742 1357 |
| Website | https://www.biopathholdings.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 1 |
Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. Its drug delivery and antisense technology is the DNAbilize, a platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification that is intended to protect the DNA from destruction by the body's enzymes when circulating in vivo, incorporated inside of a lipid bilayer having neutral charge. The company's lead drug candidate is the Prexigebersen (BP1001), which is in phase 2 clinical trial for the treatment of untreated acute myeloid leukemia (AML). It is also developing BP1001-A, which is in phase 1 clinical trial for treatment of solid tumors, including ovarian, endometrial and pancreatic cancer, as well as in preclinical trial to treat obesity and related metabolic diseases; Liposomal Bcl-2 (BP1002), which is in phase 1 clinical trial to treat refractory/relapsed lymphoma and refractory/relapsed chronic lymphocytic leukemia; and Liposomal STAT3 (BP1003), which is preclinical trial for the treatment of pancreatic cancer, non-small cell lung cancer, and AML. Bio-Path Holdings, Inc. was founded in 2007 and is based in Bellaire, Texas.
Q&A For Bio-Path Stock
What is a current BPTH stock price?
Bio-Path BPTH stock price today per share is 0.04 USD.
How to purchase Bio-Path stock?
You can buy BPTH shares on the OTC Markets OTCPK exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Bio-Path?
The stock symbol or ticker of Bio-Path is BPTH.
Which industry does the Bio-Path company belong to?
The Bio-Path industry is Biotechnology.
How many shares does Bio-Path have in circulation?
The max supply of Bio-Path shares is 50.3M.
What is Bio-Path Price to Earnings Ratio (PE Ratio)?
Bio-Path PE Ratio is now.
What was Bio-Path earnings per share over the trailing 12 months (TTM)?
Bio-Path EPS is -1.14 USD over the trailing 12 months.
Which sector does the Bio-Path company belong to?
The Bio-Path sector is Healthcare.
Bio-Path BPTH included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| US Tech Composite IXIC | 26853.98 USD — |
-0.89
|
8.32B USD — | 26769.16 USD — | 27130.88 USD — | — - | 8.32B USD — |
| US Tech Composite Total Return XCMP | 33104.2 USD — |
-0.89
|
— — | 32999.64 USD — | 33445.55 USD — | — - | — — |
| US Tech Capital Market Composite RCMP | 148.96 USD — |
-1.84
|
— — | 148.23 USD — | 151.02 USD — | — - | — — |
| US Tech Health Care IXHC | 1133.51 USD — |
+1.54
|
— — | 1113.35 USD — | 1133.95 USD — | — - | — — |
- {{ link.label }} {{link}}